HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical, hemodynamic, and neuroendocrine effects of chronic prazosin therapy for congestive heart failure.

Abstract
We report our hemodynamic, clinical, and neuroendocrine observations during long-term (8 weeks) prazosin (PZN) administration to assess the efficacy of this agent in the long-term therapy of congestive heart failure (CHF) and to emphasize the potential role of neuroendocrine mechanisms in the determination of overall drug effect. During long-term PZN therapy there is improvement in functional status, exercise tolerance, and left and right ventricular ejection fractions. However, we also observed an increase in fluid retention and attenuation of the initial hemodynamic and clinical responses to the drug. Plasma renin activity and plasma norepinephrine concentration are increased during long-term PZN therapy despite clinical and hemodynamic improvement and potentially may be involved in the pathogenesis of the increased fluid retention and hemodynamic attenuation. Three pharmacologic considerations appear relevant to the use of an alpha-adrenergic antagonist such as PZN in CHF therapy: (1) the drug response may be related to the baseline level of sympathetic tone. (2) The dose-response pattern exhibits a plateau phase, beyond which higher doses cause little further effect. (3) The overall drug effect is the sum of its direct actions and the secondary actions of the neuroendocrine response it elicits.
AuthorsW S Colucci, G H Williams, E Braunwald
JournalAmerican heart journal (Am Heart J) Vol. 102 Issue 3 Pt 2 Pg. 615-21 (Sep 1981) ISSN: 0002-8703 [Print] United States
PMID6115578 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Hormones
  • Neurotransmitter Agents
  • Quinazolines
  • Receptors, Adrenergic, alpha
  • Renin
  • Prazosin
Topics
  • Drug Tolerance
  • Heart Failure (drug therapy)
  • Hemodynamics (drug effects)
  • Hormones (metabolism)
  • Humans
  • Neurotransmitter Agents (metabolism)
  • Prazosin (therapeutic use)
  • Quinazolines (therapeutic use)
  • Receptors, Adrenergic, alpha (drug effects)
  • Renin (blood)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: